Au W Y, Chan K W, Lui S L, Lam C C, Kwong Y L
Department of Medicine, University of Hong Kong, Queen Mary Hospital, Hong Kong.
Am J Kidney Dis. 1999 Nov;34(5):889-93. doi: 10.1016/S0272-6386(99)70047-8.
The myeloproliferative disorders (MPDs) are clonal disorders of the hematopoietic stem cell and classified as polycythemia vera (PV), essential thrombocythemia (ET), or agnogenic myeloid metaplasia (AMM), depending on the main hematopoietic lineage involved. Primary renal parenchymal lesions are not commonly reported in these cases. We conducted a retrospective analysis of 138 consecutive patients with MPD to determine the frequency of renal parenchymal complications. Five patients (3.6%) (two PV, two ET, one AMM) were found to have focal segmental glomerulosclerosis (FSGS) and diffuse mesangial sclerosis, presenting as proteinuria in all the cases and progressing to chronic renal failure in two cases. A possible common risk factor was a high platelet count, because abnormal platelet activation in MPD has been shown to contribute to the development of glomerulosclerosis. The pathophysiologic basis of our observations and the implications in management of MPD patients remain to be studied.
骨髓增殖性疾病(MPD)是造血干细胞的克隆性疾病,根据主要受累的造血谱系分为真性红细胞增多症(PV)、原发性血小板增多症(ET)或特发性骨髓化生(AMM)。这些病例中一般不会报告原发性肾实质病变。我们对138例连续性MPD患者进行了回顾性分析,以确定肾实质并发症的发生率。发现5例患者(3.6%)(2例PV、2例ET、1例AMM)患有局灶节段性肾小球硬化(FSGS)和弥漫性系膜硬化,所有病例均表现为蛋白尿,2例进展为慢性肾衰竭。一个可能的共同危险因素是血小板计数高,因为已表明MPD中异常的血小板活化会导致肾小球硬化的发展。我们观察结果的病理生理基础以及对MPD患者管理的意义仍有待研究。